Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High-density lipoprotein remodelled in hypercholesterolaemic blood induce epigenetically driven down-regulation of endothelial HIF-1α expression in a preclinical animal model

  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Escate, Rafael|||0000-0002-8448-7244
  • Casaní, Laura|||0000-0002-0139-4588
  • Padró, Teresa|||0000-0003-1921-954X
  • Peña, Esther|||0000-0003-2750-0614
  • Arderiu, Gemma|||0000-0001-8598-4106
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
High-density lipoproteins (HDLs) are circulating micelles that transport proteins, lipids, and miRNAs. HDL-transported miRNAs (HDL-miRNAs) have lately received attention but their effects on vascular cells are not fully understood. Additionally, whether cardiovascular risk factors affect HDL-miRNAs levels and miRNA transfer to recipient cells remains equally poorly known. Here, we have investigated the changes induced by hypercholesterolaemia on HDL-miRNA levels and its effect on recipient endothelial cells (ECs). Pigs were kept on a high-fat diet (HC; n = 10) or a normocholesterolaemic chow (NC; n = 10) for 10 days reaching cholesterol levels of 321.0 (229.7-378.5) mg/dL and 74.0 (62.5-80.2) mg/dL, respectively. HDL particles were isolated, purified, and quantified. HDL-miRNA profiling (n = 149 miRNAs) of HC- and NC-HDLs was performed by multipanel qPCR. Cell cultures of porcine aortic ECs were used to determine whether HDL-miRNAs were delivered to ECs. Potential target genes modulated by miRNAs were identified by bioinformatics and candidate miRNAs were validated by molecular analysis. In vivo effects in the coronary arteries of normocholesterolaemic swine administered HC- or NC-HDLs were analysed. Among the HDL-miRNAs, four were found in different amounts in HC- and NC-HDL (P < 0.05). miR-126-5p and -3p and miR-30b-5p (2.7×, 1.7×, and 1.3×, respectively) were found in higher levels and miR-103a-3p and miR-let-7g-5p (-1.6×, -1.4×, respectively) in lower levels in HC-HDL. miR-126-5p and -3p were transferred from HC-HDL to EC (2.5×; P < 0.05), but not from NC-HDL, by a SRB1-mediated mechanism. Bioinformatics revealed that HIF1α was the miR-126 target gene with the highest predictive value, which was accordingly found to be markedly reduced in HC-HDL-treated ECs and in miR126 mimic transfected ECs. In vivo validation confirmed that HIF1α was diminished in the coronary endothelial layer of NC pigs administered HC-HDL vs. those administered NC-HDL (P < 0.05). Hypercholesterolaemia induces changes in the miRNA content of HDL enhancing miR126 and its delivery to ECs with the consequent down-regulation of its target gene HIF1α.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Advances in HDL, Much More than Lipid Transporters

  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
High Density Lipoprotein (HDL) particles, beyond serving as lipid transporters and playing a key role in reverse cholesterol transport, carry a highly variable number of proteins, micro-RNAs, vitamins, and hormones, which endow them with the ability to mediate a plethora of cellular and molecular mechanisms that promote cardiovascular health. It is becoming increasingly evident, however, that the presence of cardiovascular risk factors and co-morbidities alters HDLs cargo and protective functions. This concept has led to the notion that metrics other than HDL-cholesterol levels, such as HDL functionality and composition, may better capture HDL cardiovascular protection. On the other hand, the potential of HDL as natural delivery carriers has also fostered the design of engineered HDL-mimetics aiming to improve HDL efficacy or as drug-delivery agents with therapeutic potential. In this paper, we first provide an overview of the molecules known to be transported by HDL particles and mainly discuss their functions in the cardiovascular system. Second, we describe the impact of cardiovascular risk factors and co-morbidities on HDL remodeling. Finally, we review the currently developed HDL-based approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

PCSK9 in Myocardial Infarction and Cardioprotection, Importance of Lipid Metabolism and Inflammation

  • Andreadou, Ioanna
  • Tsoumani, Maria
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Ikonomidis, Ignatios
  • Badimon, Lina|||0000-0002-9162-2459
  • Varga, Zoltán V.
  • Ferdinandy, Péter|||0000-0002-6424-6806
  • Schulz, Rainer
Extensive evidence from epidemiologic, genetic, and clinical intervention studies has indisputably shown that elevated low-density lipoprotein cholesterol (LDL-C) concentrations play a central role in the pathophysiology of atherosclerotic cardiovascular disease. Apart from LDL-C, also triglycerides independently modulate cardiovascular risk. Reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma LDL-C, but it is also associated with a reduction in triglyceride levels potentially through modulation of the expression of free fatty acid transporters. Preclinical data indicate that PCSK9 is up-regulated in the ischaemic heart and decreasing PCSK9 expression impacts on infarct size, post infarct inflammation and remodeling as well as cardiac dysfunction following ischaemia/reperfusion. Clinical data support that notion in that PCSK9 inhibition is associated with reductions in the incidence of myocardial infarction, stroke, and coronary revascularization and an improvement of endothelial function in subjects with increased cardiovascular risk. The aim of the current review is to summarize the current knowledge on the importance of free fatty acid metabolism on myocardial ischaemia/reperfusion injury and to provide an update on recent evidence on the role of hyperlipidemia and PCSK9 in myocardial infarction and cardioprotection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Progress in cardiac research, From rebooting cardiac regeneration to a complete cell atlas of the heart

  • Davidson, Sean M.|||0000-0001-5182-4980
  • Padró, Teresa|||0000-0003-1921-954X
  • Bollini, S.
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Duncker, D.J.
  • Evans, P.C.|||0000-0001-7975-681X
  • Guzik, T.
  • Hoefer, I.E.
  • Waltenberger, J.
  • Wojta, J.
  • Weber, C.
We review some of the important discoveries and advances made in basic and translational cardiac research in 2020. For example, in the field of myocardial infarction (MI), new aspects of autophagy and the importance of eosinophils were described. Novel approaches, such as a glycocalyx mimetic, were used to improve cardiac recovery following MI. The strategy of 3D bio-printing was shown to allow the fabrication of a chambered cardiac organoid. The benefit of combining tissue engineering with paracrine therapy to heal injured myocardium is discussed. We highlight the importance of cell-to-cell communication, in particular, the relevance of extracellular vesicles, such as exosomes, which transport proteins, lipids, non-coding RNAs, and mRNAs and actively contribute to angiogenesis and myocardial regeneration. In this rapidly growing field, new strategies were developed to stimulate the release of reparative exosomes in ischaemic myocardium. Single-cell sequencing technology is causing a revolution in the study of transcriptional expression at cellular resolution, revealing unanticipated heterogeneity within cardiomyocytes, pericytes and fibroblasts, and revealing a unique subpopulation of cardiac fibroblasts. Several studies demonstrated that exosome- and non-coding RNA-mediated approaches can enhance human induced pluripotent stem cell (iPSC) viability and differentiation into mature cardiomyocytes. Important details of the mitochondrial Ca2+ uniporter and its relevance were elucidated. Novel aspects of cancer therapeutic-induced cardiotoxicity were described, such as the novel circular RNA circITCH, which may lead to novel treatments. Finally, we provide some insights into the effects of SARS-CoV-2 on the heart.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Remote ischaemic conditioning, defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop

  • Bell, Robert M.
  • Basalay, Marina|||0000-0001-5608-3878
  • Bøtker, Hans Erik|||0000-0001-6358-8962
  • Beikoghli Kalkhoran, Siavash
  • Carr, Richard David
  • Cunningham, John
  • Davidson, Sean M.|||0000-0001-5182-4980
  • England, Timothy J.|||0000-0001-5330-8584
  • Giesz, Sara
  • Ghosh, Arjun Kumar
  • Golforoush, Pelin|||0000-0002-7543-4167
  • Gourine, Alexander V.
  • Hausenloy, Derek|||0000-0003-0729-4956
  • Heusch, Gerd
  • Ibañez, Borja|||0000-0002-5036-254X
  • Kleinbongard, Petra|||0000-0003-3576-3772
  • Lecour, Sandrine|||0000-0003-1942-8974
  • Lukhna, Kishal|||0000-0003-3637-7136
  • Ntsekhe, Mpiko|||0000-0002-0851-7675
  • Ovize, Michel
  • Salama, Alan David
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Walker, John Malcolm
  • Yellon, Derek|||0000-0001-7791-9320
The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April 2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and discuss the future of Remote Ischaemic Conditioning (RIC). This evolved from the large multicentre CONDI-2-ERIC-PPCI outcome study which demonstrated no additional benefit when using RIC in the setting of ST-elevation myocardial infarction (STEMI). The workshop discussed how conditioning has led to a significant and fundamental understanding of the mechanisms preventing cell death following ischaemia and reperfusion, and the key target cyto-protective pathways recruited by protective interventions, such as RIC. However, the obvious need to translate this protection to the clinical setting has not materialised largely due to the disconnect between preclinical and clinical studies. Discussion points included how to adapt preclinical animal studies to mirror the patient presenting with an acute myocardial infarction, as well as how to refine patient selection in clinical studies to account for co-morbidities and ongoing therapy. These latter scenarios can modify cytoprotective signalling and need to be taken into account to allow for a more robust outcome when powered appropriately. The workshop also discussed the potential for RIC in other disease settings including ischaemic stroke, cardio-oncology and COVID-19. The workshop, therefore, put forward specific classifications which could help identify so-called responders vs. non-responders in both the preclinical and clinical settings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DJ-1 administration exerts cardioprotection in a mouse model of acute myocardial infarction

  • Gallinat, Alex|||0000-0002-1521-2175
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Padró, Teresa|||0000-0003-1921-954X
  • Badimon, Lina|||0000-0002-9162-2459
Cardiovascular diseases, and particularly acute myocardial infarction (MI), are the most common causes of death worldwide. Infarct size is the major predictor of clinical outcomes in MI. The Parkinson's disease associated protein, DJ-1 (also known as PARK7), is a multifunctional protein with chaperone, redox sensing and mitochondrial homeostasis activities. Previously, we provided the evidence for a central role of endogenous DJ-1 in the cardioprotection of post-conditioning. In the present study, we tested the hypothesis that systemic administration of recombinant DJ-1 exerts cardioprotective effects in a mouse model of MI and also explored the associated transcriptional response. We report a significant treatment-induced reduction in infarct size, leukocyte infiltration, apoptosis and oxidative stress. Effects potentially mediated by G-protein-coupled receptor signaling and modulation of the immune response. Collectively, our results indicate a protective role for the exogenously administrated DJ-1 upon MI, and provide the first line of evidence for an extracellular activity of DJ-1 regulating cardiac injury in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Network-Assisted Systems Biology Analysis of the Mitochondrial Proteome in a Pre-Clinical Model of Ischemia, Revascularization and Post-Conditioning

  • Gallinat, Alex|||0000-0002-1521-2175
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Padró, Teresa|||0000-0003-1921-954X
  • Badimon, Lina|||0000-0002-9162-2459
Infarct size is the major risk predictor for developing heart failure after an acute myocardial infarction (AMI). The discovery of the conditioning phenomena (i.e., repetitive brief cycles of ischemia applied either before or after a prolonged ischemic insult) has highlighted the existence of endogenous protective mechanisms of the heart potentially limiting infarct size after revascularization. However, most cardioprotective strategies, aiming at infarct size reduction, have failed in clinical studies. Thus, cardioprotection is an unmet clinical need. In the present study, we took a network-assisted systems biology approach to explore the mitochondrial proteomic signature of the myocardium after ischemia, ischemia with direct revascularization, and ischemia with re-establishment of blood flow by postconditioning in a swine model of AMI. Furthermore, network extension with the ENCODE project human regulatory data allowed the prediction of potential transcription factors at play in the response to post-conditioning of the myocardium. Collectively, our results identify cardiac metabolism as a driver of cardioprotection, highlighting a dual role for post-conditioning promoting metabolic reprogramming of the myocardium, and a protective response mediated by VDAC2 and DJ-1 in the mitochondria.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Supplementation With Spirulina Reduces Infarct Size and Ameliorates Cardiac Function in a Pig Model of STEMI

  • Vilahur, Gemma|||0000-0002-2828-8873
  • Sutelman, Pablo|||0000-0002-4380-0900
  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Radikė, Monika|||0000-0002-4004-4150
  • Schoch, Leonie|||0000-0002-2492-6807
  • Casaní, Laura|||0000-0002-0139-4588
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Padró, Teresa|||0000-0003-1921-954X
  • Badimon, Lina|||0000-0002-9162-2459
Myocardial infarction (MI) is the clinical manifestation of atherosclerotic coronary artery disease. Spirulina is an algae known to ameliorate cardiometabolic disorders and with proven anti-inflammatory and anti-oxidant effects. We investigated, in a highly translatable animal model, whether oral supplementation with spirulina protects against the deleterious effects triggered by ST-elevation MI (STEMI). Pigs were fed a regular diet supplemented with spirulina (1 g/animal/bid) or placebo-control for 10 days. Thereafter, animals were subjected to 1.5 h percutaneous balloon-induced coronary occlusion (STEMI) followed by 2.5 h reperfusion and then sacrificed. We assessed infarct size and cardiac function. Blood samples and infarcted and remote myocardial tissue were obtained. Spirulina supplementation reduced infarct size by 64%, increased myocardial salvage by 18%, and improved cardiac function by 30% vs. controls (p < 0.05). These benefits were associated with attenuation in DNA-oxidative damage and apoptotic markers and increased iNOS in the infarcted myocardium, higher AMPK activation in the remote myocardium, and lower myocardial MCP-1 expression. Systemically, spirulina attenuated Cox-2 expression in STEMI-activated peripheral blood mononuclear cells and enhanced TNF-α release acutely post-STEMI. Additionally, spirulina decreased weight gain progression over time (p < 0.05) without changes in lipids, glucose, liver or kidney parameters. A 10-day supplementation with spirulina exerts cardioprotection in a preclinical setting of STEMI by limiting cardiac damage and improving ventricular contractility through anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro, Implications for age-related macular degeneration

  • Romero-Vázquez, Sara|||0000-0002-2053-7230
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Figueras-Roca, Marc|||0000-0002-0548-0539
  • Llorenç, Víctor|||0000-0002-7375-1564
  • Slevin, M.
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Badimon, Lina|||0000-0002-9162-2459
  • Dick, Andrew D.
  • Molins, Blanca|||0000-0003-0941-9134
The retinal pigment epithelium (RPE) is considered one of the main targets of age-related macular degeneration (AMD), the leading cause of irreversible vision loss among the ageing population worldwide. Persistent low grade inflammation and oxidative stress eventually lead to RPE dysfunction and disruption of the outer blood-retinal barrier (oBRB). Increased levels of circulating pentameric C-reactive protein (pCRP) are associated with higher risk of AMD. The monomeric form (mCRP) has been detected in drusen, the hallmark deposits associated with AMD, and we have found that mCRP induces oBRB disruption. However, it is unknown how mCRP is generated in the subretinal space. Using a Transwell model we found that both pCRP and mCRP can cross choroidal endothelial cells and reach the RPE in vitro and that mCRP, but not pCRP, is able to cross the RPE monolayer in ARPE-19 cells. Alternatively, mCRP can originate from the dissociation of pCRP in the surface of lipopolysaccharide-damaged RPE in both ARPE-19 and primary porcine RPE lines. In addition, we found that the proinflammatory phenotype of mCRP in the RPE depends on its topological localization. Together, our findings further support mCRP contribution to AMD progression enhancing oBRB disruption.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hypercholesterolemia-Induced HDL Dysfunction Can Be Reversed, The Impact of Diet and Statin Treatment in a Preclinical Animal Model

  • Schoch, Leonie|||0000-0002-2492-6807
  • Sutelman, Pablo|||0000-0002-4380-0900
  • Suades, Rosa|||0000-0002-0193-3115
  • Casaní, Laura|||0000-0002-0139-4588
  • Padró, Teresa|||0000-0003-1921-954X
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
High-density lipoproteins (HDL) undergo adverse remodeling and loss of function in the presence of comorbidities. We assessed the potential of lipid-lowering approaches (diet and rosuvastatin) to rescue hypercholesterolemia-induced HDL dysfunction. Hypercholesterolemia was induced in 32 pigs for 10 days. Then, they randomly received one of the 30-day interventions: (I) hypercholesterolemic (HC) diet; (II) HC diet + rosuvastatin; (III) normocholesterolemic (NC) diet; (IV) NC diet + rosuvastatin. We determined cholesterol efflux capacity (CEC), antioxidant potential, HDL particle number, HDL apolipoprotein content, LDL oxidation, and lipid levels. Hypercholesterolemia time-dependently impaired HDL function (-62% CEC, -11% antioxidant index (AOI); p < 0.01), increased HDL particles numbers 2.8-fold (p < 0.0001), reduced HDL-bound APOM (-23%; p < 0.0001), and increased LDL oxidation 1.7-fold (p < 0.0001). These parameters remained unchanged in animals on HC diet alone up to day 40, while AOI deteriorated up to day 25 (-30%). The switch to NC diet reversed HDL dysfunction, restored apolipoprotein M content and particle numbers, and normalized cholesterol levels at day 40. Rosuvastatin improved HDL, AOI, and apolipoprotein M content. Apolipoprotein A-I and apolipoprotein C-III remained unchanged. Lowering LDL-C levels with a low-fat diet rescues HDL CEC and antioxidant potential, while the addition of rosuvastatin enhances HDL antioxidant capacity in a pig model of hypercholesterolemia. Both strategies restore HDL-bound apolipoprotein M content.